Herbal Medicine, Chinese Medicine, Nutrition, Homeopathy Natural Parenting/Fertility, Life Extension

Online Naturopathic Health Resource

 Specialising in Fluoride Removal Gravity Fed Water Filters since 2008

Effect of (Avandia) rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes

Rosiglitazone (Avandia) is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined. We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

See also Natural Alternatives to the Antidiabetic Drug Avandia

Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.

Nissen SE, Wolski K., Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71. Epub 2007 May 21.

enfrdeitptrues
05910223
TodayToday594
YesterdayYesterday3114
This_WeekThis_Week12672
This_MonthThis_Month59391